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Abstract
Sequence diversity in pathogen antigens is an obstacle to the development of interventions against many infectious
diseases. In malaria caused by Plasmodium falciparum, the PfEMP1 family of variant surface antigens encoded by var genes
are adhesion molecules that play a pivotal role in malaria pathogenesis and clinical disease. PfEMP1 is a major target of
protective immunity, however, development of drugs or vaccines based on PfEMP1 is problematic due to extensive
sequence diversity within the PfEMP1 family. Here we identified the PfEMP1 variants transcribed by P. falciparum strains
selected for a virulence-associated adhesion phenotype (IgM-positive rosetting). The parasites transcribed a subset of Group
A PfEMP1 variants characterised by an unusual PfEMP1 architecture and a distinct N-terminal domain (either DBLa1.5 or
DBLa1.8 type). Antibodies raised in rabbits against the N-terminal domains showed functional activity (surface reactivity
with live infected erythrocytes (IEs), rosette inhibition and induction of phagocytosis of IEs) down to low concentrations
(,10 mg/ml of total IgG) against homologous parasites. Furthermore, the antibodies showed broad cross-reactivity against
heterologous parasite strains with the same rosetting phenotype, including clinical isolates from four sub-Saharan African
countries that showed surface reactivity with either DBLa1.5 antibodies (variant HB3var6) or DBLa1.8 antibodies (variant
TM284var1). These data show that parasites with a virulence-associated adhesion phenotype share IE surface epitopes that
can be targeted by strain-transcending antibodies to PfEMP1. The existence of shared surface epitopes amongst
functionally similar disease-associated P. falciparum parasite isolates suggests that development of therapeutic
interventions to prevent severe malaria is a realistic goal.
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Introduction
The design of new drugs and vaccines against many infectious
diseases is hindered by sequence diversity in key pathogen
antigens [1]. This is a particular problem in the deadliest form of
human malaria caused by P. falciparum, in which important
targets of protective immunity are highly variable antigens
(PfEMP1 variants, encoded by var genes) expressed on the surface
of IEs [2]. Every P. falciparum isolate has 50–60 diverse PfEMP1
variants, and the PfEMP1 repertoires of different isolates are
largely non-overlapping [3–6]. PfEMP1 variants are expressed in
a mutually exclusive fashion, and transcriptional switching from
one var gene to another results in antigenic variation of P.
falciparum IEs [7]. PfEMP1 variants sampled from broad global
parasite populations show essentially unlimited amino acid
sequence diversity [5,8], making PfEMP1 an extremely challeng-
ing therapeutic target [9,10]. Surface-reactive antibodies to
PfEMP1 on live IEs that occur after natural infections [11,12]
or after immunization with recombinant PfEMP1 domains
[12,13] are predominantly variant- and strain-specific, as
expected for highly variable parasite antigens. However, children
living in endemic areas develop antibodies during the first few
years of life that protect against life-threatening malaria [14]
suggesting that strain-transcending antibody responses may occur
[15], or that the parasites that cause severe malaria are of
restricted antigenic types [16,17]. Antigenically-restricted subsets
of parasite surface antigens that induce strain-transcending
antibodies have not yet been identified.
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In addition to their role in immunity and immune evasion,
PfEMP1 variants are adhesion molecules that mediate interactions
with a variety of human cell types and surface receptors [18,19].
Three major PfEMP1 families (A, B and C, based on conserved
upstream sequence and genomic location) differ in their adhesive
function [18]. Group B and C variants (approximately 40–50
variants per haploid parasite genome) bind to the endothelial
protein and scavenger receptor CD36 [20,21]. In contrast, Group
A variants (approximately 10 variants per haploid parasite
genome) do not bind CD36 [20,21]. The binding functions of
most Group A variants are currently unknown, except for several
examples of Group A variants that mediate rosetting
[12,13,22,23], an adhesion phenotype in which IEs bind to
uninfected Es [24]. The fact that different antigenic forms of
PfEMP1 mediate different binding phenotypes means that
transcriptional switching of var genes not only results in antigenic
variation, but can also result in alteration of the adhesion
phenotype of IEs [25] and the propensity to cause disease. Several
studies have examined the link between var gene transcription and
clinical disease, and most show that transcription of Group A var
genes is linked to severe malaria in a variety of geographical
settings [26–29] and laboratory experiments [30], whereas
transcription of B and C var genes occurs in less virulent infections
causing uncomplicated disease [26–29].
Rosetting is currently the adhesion phenotype mostly clearly
linked to parasite virulence, being associated with life-threatening
malaria in African children [31–35] and high parasite burden in a
primate malaria model [36]. Rosetting causes pathological
obstruction to microvascular blood flow [37] and human
erythrocyte polymorphisms that reduce the ability of P. falciparum
to form rosettes confer substantial protection against severe
malaria [38,39]. P. falciparum rosetting parasites can be divided
into two distinct phenotypes: those that bind IgM natural
antibodies (‘‘non-immune’’ IgM) from normal human plasma/
serum onto the surface of IEs (here called IgM-positive rosetting)
[40,41] and those that do not (IgM-negative rosetting). Non-
immune IgM-binding is thought to strengthen the adhesion
interactions between infected and uninfected Es in rosettes
[40,42,43], and may also play a role in immune evasion by
masking key epitopes [44]. Previous studies of PfEMP1 and
rosetting have focussed on parasites with the IgM-negative
phenotype [12,13,22,23,45]. Detailed examination of IgM-positive
rosetting parasites has been neglected to date, despite the clinical
importance of this phenotype. A previous study of 57 clinical
isolates from Kenyan children with severe and uncomplicated
malaria found that 46 isolates formed rosettes (with rosette
frequency ranging from 1% to 79%) and all rosetting isolates
showed IgM-binding [41]. There was a strong positive correlation
between rosette frequency and the percentage of IgM-positive IEs
(r=0.804, p,0.001, Spearman correlation). IgM-positive IEs
were not seen in parasite strains showing other common adhesion
phenotypes such as CD36 binding, ICAM-1 binding or platelet-
mediated clumping [41]. IgM-positive IEs are also found in
chondroitin sulfate A-binding parasite strains linked to pregnancy
malaria [46], however parasites with this phenotype are rare in
children [47]. Therefore in malaria infections of young children,
IgM-binding and rosetting are linked phenotypes and are
associated with severe disease [41].
Here we examine representatives from both major rosetting
phenotypes to identify PfEMP1 variants responsible for rosetting
and to investigate the hypothesis that PfEMP1 variants from P.
falciparum parasites with a shared virulence-associated adhesion
phenotype might share surface epitopes. We found that IgM-
positive rosetting parasites transcribe a subset of PfEMP1 variants
and that immunization with the N-terminal domain of these
variants generates strain-transcending antibodies that recognise
geographically diverse IgM-positive rosetting strains.
Results
Identification of PfEMP1 variants transcribed by rosetting
parasites
To identify the key surface antigens of rosetting parasites, five P.
falciparum laboratory strains originating from different countries
were grown in vitro and selected for the rosetting phenotype. Three
IgM-positive (HB3R+, TM284R+ and IT/PAR+) and two IgM-
negative (Muz12R+ and TM180R+) rosetting strains were studied
(see ‘‘Materials and Methods’’ for full details of parasite strains).
For each strain, isogenic rosette positive (R+) and rosette negative
(R2) populations were selected in parallel [22,48], and their var
gene transcription profiles examined by analysis of short PfEMP1
sequence tags [27]. The rosette-specific variant in each strain was
identified as the predominant var gene transcribed by the rosetting
population (comprising between one third to one half of all the var
gene sequences detected) that was absent/rare in the non-rosetting
population (an example is shown in Table S1). The full-length
sequence of each predominant rosette-specific var gene was
obtained from the sequence tag as described in the Materials
and Methods. The rosetting variants were mostly Group A
(Figure 1a), defined by the presence of a conserved upstream
sequence (UpsA) and a characteristic N-terminal domain type
(called DBLa1 or ‘‘Cys2’’) that is associated with severe malaria
[20,27,29]. The variants from the IgM-positive rosetting parasites
form a distinct subset that share an unusual PfEMP1 architecture,
containing a triplet of domains that occur rarely in PfEMP1 (DBLe
and DBLf) [6] preceding the transmembrane region. The binding
site for non-immune IgM lies within these DBLe/f domains
[49,50](AG and JAR, unpublished data). The IgM-binding
domain triplet is linked via at least one other domain (DBLc) to
a typical Group A PfEMP1 head-structure [18,20,51] (Figure 1a).
DBLa domains from Group A PfEMP1 variants fall into eight
subclasses (DBLa1.1 to DBLa1.8) based on sequence homology
[6]. The rosetting variants described previously (ITvar9 [22], Palo
Author Summary
Malaria remains one of the world’s most deadly diseases.
Life-threatening malaria is linked to a process called
rosetting, in which malaria parasite-infected red blood
cells bind to uninfected red cells to form aggregates that
block blood flow in vital organs such as the brain. Current
efforts to develop drugs or vaccines against rosetting are
hindered by variation in the parasite rosette-mediating
proteins, found on the surface of infected red cells. We
studied these parasite-derived surface proteins and
discovered that although they are variable, they share
some common features. We raised antibodies against the
rosette-mediating proteins, and found that they cross-
reacted with multiple rosetting parasite strains from
different countries around the world, including samples
collected directly from African children with severe
malaria. These findings provide new insights into malaria
parasite interactions with human cells, and provide proof
of principle that variable parasite molecules from virulent
malaria parasites can induce strain-transcending antibod-
ies. Hence, this work provides the foundation for the
development of new therapies to treat or prevent life-
threatening malaria.
Strain-Transcending PfEMP1 Antibodies
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Alto varO [23] and PF13_0003 [12]) are all of the DBLa1.6
subclass. The rosette-specific variants identified here are DBLa1.5
(HB3var6 and Muz12var1), DBLa1.8 (TM284var1 and ITvar60)
or DBLa2 (a Group B type, TM180var1) [6].
Despite the observed similarities in PfEMP1 architecture, there
was considerable sequence diversity amongst the rosette-specific
variants from different parasite strains, with the rosette-mediating
domain (NTS-DBLa) [12,22,23] showing pair-wise amino acid
identities of between 38.9% (ITvar60:TM180var1) and 62.6%
(ITvar60:TM284var1) (Table S2 and Figure S1). The other
extracellular domains from the rosetting variants do not show high
levels of amino acid identity apart from the first CIDR domain of
TM284var1 and ITvar60 (82.2%) and the first CIDR domain of
HB3var6 and Muz12var1 (81.1%; see Tables S2, S3, S4, S5, S6,
S7 for pair-wise amino acid identities for all domain types).
Northern blots were carried out to determine whether rosetting
parasite-specific PfEMP1 variants had been identified. For each
parasite strain, a specific PfEMP1 domain from the rosetting-
associated variant identified above was used to probe RNA from
isogenic pairs of rosetting and non-rosetting parasites. The
rosetting-associated PfEMP1 probe detected a transcript in
rosetting parasites (arrowed) that was absent/weak in isogenic
non-rosetting parasites (Figure 1b; shown previously for TM284
[50]). The presence of other transcribed var genes in the non-
rosetting parasites was shown using an Exon II probe that
identifies all var genes (Figure 1b). These data show that the
transcriptional profiling experiments correctly identified full-length
var genes whose transcription is specific to rosette-selected
parasites.
In order to raise antibodies against the rosetting PfEMP1
variants, the N-terminal NTS-DBLa region of each rosetting
parasite-specific variant was expressed as a recombinant protein in
E. coli [13], with a shift in mobility of the recombinant proteins
upon reduction showing the presence of disulfide bonds in these
Figure 1. Identification of key surface antigens (Group A PfEMP1 variants) of P. falciparum rosetting parasites and production of
recombinant proteins for immunization. a) PfEMP1 domain architecture of the predominantly expressed variants from P. falciparum rosetting
laboratory strains. The previously described rosetting variant ITvar9 [13,22,45] is shown for comparison. Domain types are based on conserved motifs
[6,51]. NTS: N-Terminal Segment; DBL: Duffy Binding Like; CIDR: Cysteine-rich InterDomain Region; ATS: Acidic Terminal Segment; TM:
TransMembrane region. *The IT isolate was originally from Brazil, however following cross-contamination of parasite cultures in the early1980s,
current IT/FCR3 strains are thought to be of South-East Asian origin [88]. The Genbank accession numbers for these sequences are Y13402 (ITvar9/
R29var1), EF158099 (ITvar60), JQ684046 (TM284var1), JQ684047 (TM180var1) and JQ684048 (Muz12var1). The HB3var6 sequence can be obtained from
http://www.broadinstitute.org/annotation/ genome/plasmodium_falciparum_spp/MultiHome.html gene reference PFHG_02274.1. b) Northern blots
of RNA from isogenic rosetting (R+) and non-rosetting (R2) parasites probed with a PfEMP1 domain from the rosette-specific variant for each strain
(R+ DBL probe, high stringency) and with an Exon II probe (moderate stringency), which detects all var genes [50]. Arrows indicate the major rosette-
specific var gene transcript in each strain. Equal loading of R+ and R2 RNA was confirmed by staining with ethidium bromide (Et Br). c) Production of
recombinant NTS-DBLa domains in E. coli to immunize rabbits. 1: TM180var1, 2: Muz12var1, 3:TM284var1, 4: ITvar60, 5:HB3var6. M: molecular weight
marker; R: reduced; NR: non-reduced.
doi:10.1371/journal.ppat.1002665.g001
Strain-Transcending PfEMP1 Antibodies
PLoS Pathogens | www.plospathogens.org 3 April 2012 | Volume 8 | Issue 4 | e1002665
cysteine-rich proteins (Figure 1c). NTS-DBLa was chosen because
it is the domain that binds erythrocytes to bring about rosetting
[22,23], and variant-specific antibodies to this region were the
most effective in inhibiting rosetting in previous studies [13,23].
Polyclonal antibodies against PfEMP1 recognize the
surface of live IEs of homologous P. falciparum rosetting
strains
The recombinant proteins were used to immunize rabbits [13],
to raise polyclonal antibodies to the PfEMP1 variants from each of
the five different P. falciparum rosetting strains. Two rabbits were
immunised per antigen and the resulting antisera were tested
against the antigen used for immunization in an ELISA. Very
similar responses were obtained from each pair of rabbits, with
ELISA values (50% of maximum titre) of .1/40,000 (HB3var6
and Muz12var1) or .1/100,000 (TM284var1, ITvar60 and
TM180var1).
To determine if the antibodies recognised native PfEMP1 on
the surface of live IEs, they were tested by ImmunoFluorescence
Assay (IFA) and flow cytometry against homologous parasites
(defined here as meaning antibodies against a particular PfEMP1
variant being tested against the parasite strain from which that
variant was identified as the predominant PfEMP1). The antisera
to each of the five variants gave punctate surface fluorescence of
homologous IEs that is characteristic of PfEMP1 antibody staining
[13,52–54] (Figure 2a middle panel). Between 30–75% of IEs in
each culture showed punctate staining, similar to the rosette
frequency in these laboratory strains (which varies from cycle to
cycle due to var gene switching and frequency of rosette selection)
(Table S8). Depending on the plane of focus, the staining of live
IEs in IFA wet preparations can also be seen as rim fluorescence as
described in some previous publications [23] (Figure 2a lower
panel). The pre-immune serum from each rabbit and serum from
a non-immunized control rabbit did not show punctate staining of
IEs by IFA. These negative controls show faint, smooth
background fluorescence over both infected and uninfected Es
by fluorescence microscopy (Figure 2b, lower panel). Antibodies to
a non-rosetting Group A PfEMP1 variant HB3var3 (a variant
transcribed by non-rosetting parasites that bind to brain
endothelial cells, Claessens and Rowe et al, submitted) gave the
same negative IFA appearance as control non-immunized rabbit
serum shown in Figure 2b. For all immunizations, the antisera
from the two rabbits per antigen gave similar results. For each
antigen, the antiserum giving the brightest IFA signal at 1/50
dilution was chosen for purification of total IgG for subsequent
experiments.
By flow cytometry using homologous antibody/parasite combi-
nations, dot plots showed a population of IEs that were surface
stained with PfEMP1 antibodies (Figure 2c, middle column, upper
right quadrants). IgG from a control non-immunized rabbit did
not stain IEs (Figure 2c, left column). One of the features of the
PfEMP1 family is that most variants show unusual sensitivity to
trypsin and can be cleaved from the surface of IEs by very low
concentrations of protease [55]. To determine whether the
antibodies raised to PfEMP1 NTS-DBLa domains were recognis-
ing PfEMP1-like molecules on the surface of live IEs, we carried
out immunofluorescent staining and flow cytometry after treat-
ment of live IEs with a low concentration of trypsin. We found that
for parasite strains HB3R+, TM284R+, Muz12R+, TM180R+
and IT/R29, the staining with homologous PfEMP1 antibodies
was abolished by mild trypsinisation (Figure 2c, right column),
consistent with recognition of PfEMP1. For parasite strain IT/
PAR+ however, antibodies to ITvar60 detected IE surface
molecules that were resistant to proteolytic cleavage, even up to
1 mg/ml of trypsin (Figure 2c, right column). This suggests either
that the ITvar60 PfEMP1 variant is trypsin-resistant or that the
antibodies to ITvar60 are recognising other (non-PfEMP1,
trypsin-resistant) molecules on the IE surface. Western blots to
investigate these possibilities showed that IT/PAR+ parasites do
express a trypsin-resistant PfEMP1 variant (Figure S2a and Text
S1), and that the rabbit polyclonal antibodies to ITvar60 recognise
high molecular weight parasite-specific trypsin-resistant molecules,
and no other parasite-specific molecules were identified (Figure
S2c and Text S1).
For the IgM-positive rosetting strains (HB3R+, TM284R+ and
IT/PAR+), we tested whether the homologous PfEMP1 antibodies
recognized the IgM-positive IEs by dual colour IFA. For all three
strains, the same individual IEs were stained with anti-human IgM
(red) and anti-PfEMP1 (green) (HB3R+ parasites shown in Figure 3
and TM284R+ parasites shown in Figure S3). For all three strains,
94–100% of the IEs that stained with the PfEMP1 antibodies were
IgM-positive. Similarly, 91–100% of the IgM-positive IEs were
positive with the PfEMP1 antibodies. Secondary antibody-only
controls (not shown) and species-specific Ig controls (Figure 3, right
column) were negative by IFA. In addition, combinations of rabbit
PfEMP1 antibodies with anti-mouse secondary and mouse human
IgM antibody with anti-rabbit secondary were also negative
(Figure S3b), ruling out the possibility of non-specific binding of
the Alexa Fluor-conjugated secondary antibodies. Additional
positive controls (mouse anti-human IgM alone with anti-mouse
secondary and rabbit PfEMP1 antibody alone with anti-rabbit
secondary) showed the expected positive staining (not shown). The
IgM staining did not differ in the presence or absence of the
PfEMP1 antibodies (not shown), suggesting that the binding of
antibodies to the N-terminal domains of PfEMP1 does not
interfere with IgM-binding towards the C-terminus of the
molecule [49,50].
These experiments show that for parasite strains HB3R+,
TM284R+ and IT/PAR+, the homologous PfEMP1 antibodies
are specifically recognising the IgM-binding IE population, which
are the rosette-forming cells ([41] and Table S9). This confirms
that transcriptional profiling correctly identified the predominant
PfEMP1 variant (Figure 1) from the IgM-positive rosette-selected
parasite culture of each strain.
Polyclonal antibodies against PfEMP1 recognize the
surface of live IEs of heterologous P. falciparum rosetting
strains
To determine whether the PfEMP1 antibodies show surface
reactivity when tested against heterologous parasite strains, we
carried out live IE IFA and flow cytometry with heterologous
antibody/parasite combinations, and assessed the end titre of any
combinations showing positive surface fluorescence. The end titres
of homologous antibody/parasite combinations were also deter-
mined for comparison. End titres were determined using four-fold
dilutions of antibody and are defined here as the lowest
concentration giving surface staining of more than 50% of the
positive subpopulation (Figure 4a, shown for IT/PAR+ parasites
and ITvar60 antibodies).
We found that antibodies to PfEMP1 showed specific surface
reactivity against homologous parasites down to low concentra-
tions (end titres of ,2 mg/ml of total IgG, Figure 4b, rectangles in
bold). Against heterologous parasite strains, several of the PfEMP1
antibodies also showed good surface staining of other rosetting
strains down to low concentrations (,10 mg/ml of total IgG,
Figure 4b). This was especially marked with antibodies to the
PfEMP1 variants from IgM-positive rosetting parasites. For
example, ITvar60 antibodies stained TM284R+ parasites down
Strain-Transcending PfEMP1 Antibodies
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Figure 2. Polyclonal antibodies to PfEMP1 recognize the surface of homologous live infected erythrocytes (IEs). a) Live cell
ImmunoFluorescence Assay (IFA) with antibodies to HB3var6 (1/50 dilution) tested on the homologous parasite (HB3R+). DAPI staining (1 mg/ml)
shows the position of IEs (upper panel; scale bar 10 mm). PfEMP1 antibody is detected by highly cross-absorbed Alex Fluor 488-conjugated anti-rabbit
IgG (1/500 dilution, middle and lower panels). Specific staining of IEs is seen as punctate fluorescence over the whole IE surface (middle panel, white
arrows). Unstained IEs show pale smooth background fluorescence (middle panel, white arrowhead). If the plane of focus is adjusted, stained IEs
show mainly rim fluorescence (lower panel). Rosettes are not seen in these images because they are disrupted by the PfEMP1 antibodies. b) IFA with
Strain-Transcending PfEMP1 Antibodies
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to low concentrations and vice versa (TM284var1 antibodies
stained IT/PAR+ parasites). IT/PAR+ parasites were also stained
with low concentrations of HB3var6 antibodies (Figure 4b). Within
each parasite population, dual colour IFA showed that the
heterologous PfEMP1 antibodies recognised the IgM-positive IE
population (shown for TM284R+ parasites, Figure S3). Further-
more, heterologous antibodies recognised trypsin-sensitive surface
molecules on parasite strain TM284R+, consistent with binding to
PfEMP1 (Figure S4a). While for parasite strain IT/PAR+,
heterologous antibodies recognised trypsin-resistant molecules
(Figure S4b) as seen with the homologous antibody (Figure 2).
The antibodies raised to the PfEMP1 variants from IgM-positive
rosetting parasites also showed some reactivity with the IgM-
negative rosetting strains (Muz12R+, TM180R+ and IT/R29),
although high concentrations were required (100–400 mg/ml of
total IgG, Figure 4b). These concentrations still represent a
considerable dilution of whole serum (equivalent to 1/100 to1/25
dilution) therefore they are potentially relevant in vivo. Antibodies
raised to the PfEMP1 variants from IgM-negative rosetting
parasites were predominantly variant- and strain-specific and
showed only limited surface reactivity with the other rosetting
laboratory strains (Figure 4b), consistent with previous data
[12,13].
The PfEMP1 antibodies were also tested for surface reactivity
against parasite lines showing other adhesion phenotypes. We
found that antibodies raised against rosetting PfEMP1 variants did
not recognise parasites showing other adhesion phenotypes
(Figure 4b), including binding to CD36 or ICAM-1 (parasites
expressing Group B and C var genes) or binding to brain
endothelial cells (parasites expressing an alternative sub-set of
group A and B/A var genes, Claessens and Rowe et al, submitted).
Taken together, the above data show that polyclonal antibodies
generated against PfEMP1 variants from IgM-positive rosetting
strains have strain-transcending properties, as they show surface
reactivity with heterologous rosetting strains, especially those
showing IgM-positive rosetting. This suggests shared surface
epitopes amongst heterologous rosetting PfEMP1 variants.
We examined whether similar patterns of variant-specific and
cross-reactive antibody responses to those shown above were
found when each total IgG preparation was tested in an ELISA
against the panel of NTS-DBLa recombinant proteins used for
immunization. We found that although each antibody showed
high ELISA O.D. readings against the homologous immunizing
antigen, they also showed widespread recognition of other DBL
domains using this method (Figure S5). These data confirm earlier
findings of Vigan-Womas et al [12] who showed that PfEMP1
antibody recognition of DBL domains by ELISA does not
successfully predict surface reactivity with live IEs.
Strain-transcending polyclonal PfEMP1 antibodies are
functionally active
Surface recognition of live IEs by antibodies in vivo is likely to
lead to parasite clearance via effector mechanisms such as
phagocytosis or complement-mediated lysis [14]. Rosette-inhibi-
tion may also be desirable in vivo to prevent pathological
microvascular obstruction. We therefore examined whether the
surface reactivity by homologous and heterologous PfEMP1
antibodies shown in Figure 4b, translated into demonstrable
effector functions. The PfEMP1 antibodies showed potent rosette-
inhibition against homologous parasite strains with 50% inhibitory
concentrations (IC50) for rosetting between 0.8–8 mg/ml of total
IgG (Figure 5a, red curves), except for TM180R+, which was not
inhibited (Figure 5a, brown curve) despite good surface reactivity
antibodies from a non-immunized control rabbit (1/50 dilution) tested on HB3R+ parasite culture. Upper panel: DAPI staining shows the position of
IEs (scale bar 10 mm). Lower panel: highly cross-absorbed Alex Fluor 488-conjugated anti-rabbit IgG gives no specific staining on IEs. Camera
exposure settings and image handling for Alexa Fluor 488 images were identical for PfEMP1 antibody and control pictures. c) Flow cytometry of live
IEs of P. falciparum rosetting strains stained with homologous PfEMP1 antibodies (HB3R+ parasites with HB3var6 antibodies; TM284R+ parasites with
TM284var1 antibodies; IT/PAR+ parasites with ITvar60 antibodies; Muz12R+ parasites with Muz12var1 antibodies; TM180R+ parasites with TM180var1
antibodies; IT/R29 parasites with ITvar9 antibodies). Negative control rabbit IgG from a non-immunized rabbit (left column) and PfEMP1 antibodies
(middle column) were tested at 100 mg/ml of total IgG. IEs were stained with Hoechst and rabbit IgG bound to the surface of erythrocytes was
detected with highly cross-absorbed Alex Fluor 488-conjugated anti-rabbit IgG at 1/500 dilution. The percentage of Hoechst-stained IEs that were
stained with Alexa Fluor 488 is shown in the upper right quadrant. The IE molecules recognised by PfEMP1 antibodies were sensitive to trypsin (right
column) (10 mg/ml trypsin for 5 mins at room temperature (RT), followed by 1 mg/ml of trypsin inhibitor for 5 mins at RT), except for parasite strain
IT/PAR+, in which the surface molecules recognized by ITvar60 antibodies were trypsin-resistant, even at 1 mg/ml of trypsin. Rabbit polyclonal
antibodies to ITvar9 expressed by IT/R29 rosetting parasites have been reported previously [13], and are included here in all figures for comparison
with the newly generated antibodies to the five other rosetting strains.
doi:10.1371/journal.ppat.1002665.g002
Figure 3. Polyclonal antibodies to PfEMP1 recognize IgM-
positive IEs. HB3R+ live IEs were stained with a mixture of mouse mAb
anti-human IgM (1/500 dilution) and rabbit polyclonal HB3var6 NTS-
DBLa antibodies (20 mg/ml) (left column) or a mixture of mouse IgG
isotype control and non-immunized rabbit IgG control (right column).
Secondary incubation was with a mixture of Alexa 488 conjugated anti-
rabbit IgG (1/1000) and Alexa 594-conjugated anti-mouse IgG (1/1000).
IEs were stained with DAPI (1 mg/ml; scale bar 10 mm). The PfEMP1
antibodies (left column, bottom panel) stained IEs that were also
positive for human IgM (left column, middle panel). Camera exposure
settings were identical for PfEMP1 antibodies and controls except for
human IgM/PfEMP1 with Alexa Fluor 488 which was taken at a shorter
exposure setting (20 msecs) than the control (200 msecs), due to the
brightness of the signal.
doi:10.1371/journal.ppat.1002665.g003
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(Figure 4b). Parasite strains TM284R+, IT/PAR+ and TM180R+
all showed rosette inhibition by heterologous antibodies (Figure 5a,
blue curves). Two repeated experiments with TM180R+ con-
firmed the lack of rosette inhibition by homologous antibody and
successful rosette inhibition by heterologous TM284var1 antibody.
At a higher concentration (1 mg/ml of total IgG, equivalent to 1/
10 dilution of serum) the cross-reactivity in rosette inhibition was
even more marked, with all strains being inhibited by antibodies to
at least one of the IgM-positive rosetting PfEMP1 variants
(Figure 5b). These concentrations are equivalent to those seen
with naturally-acquired rosette-disrupting antibodies in malaria-
exposed patients which show activity at 1/10 or 1/5 dilution [56].
The antibodies to PfEMP1 variants from IgM-positive rosetting
parasites were also shown to have cross-reactive opsonising effects,
by inducing the phagocytosis of homologous and heterologous IEs
(Figure 5c and Figure S6). In contrast, antibodies to PfEMP1
variants from IgM-negative rosetting parasites only effectively
opsonised homologous parasites (Figure 5c and Figure S6).
Polyclonal antibodies against PfEMP1 show surface-
reactivity and rosette inhibition against P. falciparum
clinical isolates
Having shown that polyclonal antibodies to PfEMP1 variants
from IgM-positive rosetting parasites show heterologous surface
reactivity and biological effector functions against rosetting P.
falciparum laboratory strains, we carried out a preliminary
experiment to examine recognition of clinical isolates from sub-
Saharan Africa. The clinical isolates were cryopreserved from
previous studies and were selected because they contained at least
20% of IEs in rosettes (see ‘‘Materials and Methods’’ for further
details of the clinical isolates origins). Ten clinical isolates were
thawed, and all but one contained IgM-positive IEs detected by
IFA with an anti-human IgM monoclonal antibody (mAb). For six
isolates, the percentage of IgM-positive IEs was very similar to the
rosette frequency, suggesting that the majority of rosetting
parasites were of the IgM-positive phenotype (Figure 6a, above
the dotted line). For three isolates, the percentage of IgM-positive
IEs was substantially lower than the rosette frequency, suggesting
either a sub-population of IgM-positive rosetting parasites within a
larger population of IgM-negative rosetting parasites, or the
presence of a sub-population of IgM-positive non rosetting cells
(Figure 6a, below the dotted line). One isolate (MAL103) showed
no IgM-positive IEs, and two recently culture-adapted, rosette-
selected Kenyan isolates (9197 and SA075) were also IgM-negative
(Figure 6a).
The panel of PfEMP1 antibodies and controls was tested for
surface reactivity with the clinical isolates by IFA (all isolates) and
by flow cytometry (five isolates). Positive surface staining was
defined as punctate surface fluorescence specific to live IEs in IFA
(similar to that shown in Figures 2 and 3) or by a population of
Hoechst-positive, Alexa Fluor 488-positive IEs by flow cytometry
(Figure 6b). Remarkably, all of the IgM-positive rosetting clinical
isolates contained sub-populations of cells that stained with either
HB3var6 antibodies or TM284var1 antibodies (Figure 6). The
proportions of PfEMP1 antibody positive and IgM-positive cells
were closely matched in each isolate (Figure 6a, Pearson
correlation r = 0.984, P,0.001). Unfortunately there was insuffi-
cient material available to carry out further experiments such as
dual colour IFA, therefore we were unable to test directly whether
Figure 4. Polyclonal antibodies to PfEMP1 recognize the
surface of homologous and heterologous live IEs. a) An example
of the determination of the immunofluorescence end titre. Flow
cytometry histograms showing the titration of antibodies to ITvar60
against IT/PAR+ parasites, compared to a non-immunized rabbit IgG
control. The end titre (defined here as the lowest concentration of
antibody giving surface staining above rabbit IgG background levels of
more than 50% of the positive IE subpopulation) was 0.1 mg/ml. b)
PfEMP1 antibodies (four-fold dilutions of total IgG starting at 400 mg/
ml) were tested in IFA or flow cytometry against P. falciparum
laboratory strains with various different adhesion phenotypes as
indicated. The end titre for each antibody/parasite combination is
shown inside each rectangle, with homologous antibody/parasite
combinations being outlined in bold. Negative controls were non-
immunized rabbit IgG control, and antibodies against NTS-DBLa from a
non-rosetting Group A PfEMP1 variant (Non-ros Group A: HB3var3,
expressed by HB3-HBEC which are non-rosetting parasites selected for
binding to human brain endothelial cells [83]). *The HB3R+ parasites
contain a subpopulation of non-rosetting HB3var3-expressing IEs (Table
S1) that are distinct from the IgM-positive HB3var6-expressing rosetting
IEs.
doi:10.1371/journal.ppat.1002665.g004
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the PfEMP1 antibodies were recognising the IgM-positive IEs.
However, the strong positive correlation between the percentages
of positive cells, and the similarities in the flow cytometry
histograms for IgM-positive and PfEMP1-positive IEs are
suggestive that both antibodies are binding to the same sub-
population of IEs (Figure 6c).
The clinical isolates were also tested in rosette inhibition assays
with the panel of PfEMP1 antibodies and controls. Rosette
inhibition was observed in four out of ten isolates, increasing to six
isolates when a pool of PfEMP1 antibodies was used (Figure 6a).
The IgM-negative clinical isolate (MAL103) and two recently
culture-adapted rosette-selected IgM-negative Kenyan strains
(9197 and SA075) were not recognized by the PfEMP1 antibodies
(Figure 6a). Therefore, in clinical isolates the PfEMP1 antibodies
only showed surface reactivity and rosette inhibition of parasites
containing populations of IgM-positive IEs.
The presence of IgM-positive rosetting variants in diverse
parasite isolates was shown further by taking the two recently
culture-adapted Kenyan strains 9197 and SA075 which initially
showed IgM-negative rosetting (Figure 6a), and selecting them for
IgM-binding using magnetic beads coated with anti-human IgM
antibodies. After three rounds of selection of strain 9197, a
population of IgM-positive rosetting parasites was obtained, which
showed surface reactivity with antibodies to HB3var6 but not with
antibodies to TM284var1 (9197 IgM-selected, Figure 7a, right
column). Dual colour IFA showed that the same subpopulation of
IEs bound both IgM and HB3var6 antibodies (Figure 7b).
Furthermore the cross-reactive HB3var6 antibodies recognised a
trypsin-sensitive surface molecule on 9197IgM+ IEs consistent
with PfEMP1 (Figure 7c). For strain SA075, after three rounds of
selection a sub-population of IgM-positive cells was obtained (10%
of IEs) that stained with antibodies to TM284var1 (not shown).
We considered the possibility that the strain-transcending effects
of the PfEMP1 antibodies against IgM-positive rosetting strains
might be explained by the antibodies cross-reacting with human
IgM (which is bound to the surface of the IEs from the culture
medium). However, the PfEMP1 antibodies did not recognise
human IgM in an ELISA (Figure 8a), and the surface reactivity
with heterologous parasite strains was maintained when the
parasites were grown in the absence of IgM (for example, IT/
PAR+ parasites show surface reactivity with TM284var1 antibod-
ies in the absence of IgM as shown in Figure 8b).
Discussion
In this work the PfEMP1 variants expressed by P. falciparum
strains representing two major rosetting phenotypes were
Figure 5. Polyclonal antibodies to PfEMP1 inhibit rosetting and
induce phagocytosis of heterologous rosetting laboratory
strains. a) Rosette inhibition assays to determine the dose-dependent
effects of PfEMP1 antibodies on homologous and heterologous
rosetting laboratory strains. Data are compared to a control with no
added antibody, which contained at least 40% of IEs in rosettes. Mean
and standard deviation of triplicate values are shown. IC50: concentra-
tion of antibody giving 50% rosette inhibition. b) Rosette inhibition
assay as above with 1 mg/ml of antibody, except for the Anti-Ros pool
which consisted of a mixture of 0.1 mg/ml of each antibody (to
HB3var6, TM284var1, ITvar60, Muz12var1, TM180var1 and ITvar9).
Controls are as for Figure 4b. c) Phagocytosis assay of opsonised IT/
PAR+ IEs co-incubated with the monocytic cell line Thp-1 [13]. Data are
shown as percentage of the positive control opsonised with a rabbit
anti-human erythrocyte antibody. Both homologous and heterologous
antibodies induce phagocytosis of IT/PAR+ IEs. Control Rab: negative
control of IgG from a non-immunized rabbit.
doi:10.1371/journal.ppat.1002665.g005
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examined. IgM-positive rosetting parasites were found to express a
distinct subset of Group A PfEMP1 variants characterised by a
DBLa1.5 or DBLa1.8 N-terminal domain and a triplet of DBLe/
DBLf domains adjacent to the transmembrane region (Figure 1).
Polyclonal antibodies raised in rabbits against the N-terminal
region of the IgM-positive rosetting variants (HB3var6,
TM284var1 and ITvar60) showed surface reactivity against
homologous parasites (Figures 2 to 4) and were potent inhibitors
of rosetting down to low concentrations (Figure 5). Furthermore,
the antibodies had strain-transcending activity at higher concen-
trations, showing surface reactivity and rosette inhibition against
heterologous laboratory strains and clinical isolates sharing the
same IgM-positive rosetting adhesion phenotype (Figures 4 to 7).
In contrast, IgM-negative rosetting parasites expressed distinct
Group A or B/A var genes and antibodies raised against them were
predominantly variant- and strain-specific, and only rarely
recognised heterologous parasite isolates, as shown in previous
work [12,22,23].
To our knowledge, this is the first report to describe the
successful induction of strain-transcending surface-reactive anti-
bodies to PfEMP1 variants implicated in severe childhood malaria.
Strain-transcending surface-reactive antibodies against the
PfEMP1 variant implicated in malaria in pregnancy (encoded by
var2CSA) have been described [57,58], however, var2CSA is a
unique well-conserved var gene with much more limited sequence
diversity than that seen in Group A var genes [59]. Cross-reactive
antibodies to PfEMP1 have also been described using methods
such a western blotting [60] and ELISA [12], however, the
relationship between recognition of PfEMP1 antigens by these
techniques and recognition of native PfEMP1 on the IE surface is
not clear. Vigan-Womas et al showed that antibodies to three
distinct rosetting Group A PfEMP1 variants cross-react by ELISA
but do not cross-react in surface reactivity with live cells [12].
Similarly, we found that recognition of DBL domains by ELISA
did not correlate well with surface reactivity (Figure S5). This may
be due to small amounts of degraded, misfolded or aggregated
material within the recombinant protein preparations used in
ELISA, or may be due to cryptic epitopes exposed in single
recombinant DBL domains that are not exposed in native
PfEMP1. These data are important because many researchers
use assays based on recombinant proteins to screen for sero-
reactivity to PfEMP1. Our data and those of Vigan-Womas et al
[12] caution against the assumption that results from assays based
on recombinant proteins provide information relevant to recog-
nition of native PfEMP1 on the infected cell surface.
The role of strain-transcending antibody responses to PfEMP1
in naturally acquired immunity to malaria remains uncertain.
Previous work suggests that African children’s’ agglutinating
antibody responses to antigens on the IE surface are predomi-
nantly variant- and strain-specific [11,15,61]. However, other
Figure 6. Polyclonal antibodies to PfEMP1 variants from laboratory strains show surface reactivity and rosette inhibition with P.
falciparum clinical isolates. a) Clinical isolates were tested with PfEMP1 antibodies and controls for surface reactivity by live cell IFA (0.4 mg/ml)
and rosette inhibition (1 mg/ml). The rosette frequency (RF), percentage of IgM-positive IEs (IgM+) and percentage of PfEMP1 antibody positive IEs
(PfEMP1+, positive with either HB3var6 or TM284var1 antibodies) are shown for each isolate. The PfEMP1 antibodies that showed surface staining
with each isolate are indicated by the shaded boxes. Positive surface staining was defined as punctate fluorescence specific to live IEs by IFA (as
shown in Figure 2). The percentage rosette inhibition is shown inside each rectangle for all isolate/antibody combinations with .25% rosette
inhibition. The controls are as for Figure 4b, and the Anti-Ros Pool is as for Figure 5b. The Anti-Ros pool was tested for rosette inhibition only. The
dotted line separates isolates in which RF closely matches the percentage of IgM-positive IEs (above) from those in which the percentage of IgM-
positive positive IEs is substantially lower than the rosette frequency (below). b) Flow cytometry of clinical isolate MAL43 with 0.4 mg/ml of total IgG
from a non-immunised rabbit (negative control, left panel) and antibodies to TM284var1 (middle panel). IEs stained with Hoechst are in the right half,
and antibody-positive IEs stained with Alexa Fluor 488 are in the upper right quadrant. An overlay of histograms (right panel) shows a clear
population of stained IEs (blue line, second peak) distinct from the rabbit IgG control (red line, single peak). c) Five clinical isolates were tested by flow
cytometry with the PfEMP1 antibody and control panel. The histograms show the negative controls, anti-PfEMP1 positive and IgM-positive IEs. The
‘‘negative PfEMP1 Ab’’ was antibody to TM180var1 and the IgM-negative control was a mouse IgG1 isotype control.
doi:10.1371/journal.ppat.1002665.g006
Figure 7. Selection for IgM yields rosetting IEs that are
recognised by heterologous polyclonal PfEMP1 antibodies. a)
The culture-adapted Kenyan isolate 9197 was selected three times with
anti-human IgM coated Dynabeads. Comparison of the unselected and
selected lines by flow cytometry showed that the IgM-selected parasites
were recognised by cross-reactive PfEMP1 antibodies to HB3var6. The
percentage of IEs stained with Alexa Fluor 488 are shown in the upper
right quadrant. b) An IFA with dual staining (AlexaFluor 488 anti-rabbit
IgG to detect PfEMP1 antibody and AlexaFluor 594 anti-mouse IgG to
detect anti-human IgM) shows that the same subpopulation of IEs
bound both IgM and HB3var6 antibodies. IEs were stained with DAPI
(1 mg/ml; scale bar 10 mm). c) Trypsin sensitivity of surface antigens
recognised by HB3var6 antibodies. Trypsinisation is as described in
Figure 2. The percentage of IEs stained with Alexa Fluor 488 are shown
in the upper right quadrant.
doi:10.1371/journal.ppat.1002665.g007
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reports suggest that strain-transcending antibodies recognizing
conserved epitopes on the surface of IEs can occur in adults
exposed to natural infections [15,62,63]. Whether the gradual
acquisition of immunity to clinical malaria is linked to acquisition
of a broad repertoire of antibodies to numerous distinct variant
types, or due to development of antibodies to conserved
determinants that cross-react against multiple strains remains
unresolved. In the case of life-threatening malaria in particular, the
role of antibodies to PfEMP1 is unclear. It is known that children
become immune to severe malaria after a small number of
infections [14,64], and that severe malaria is associated with the
acquisition of antibodies to commonly recognised variants
[16,17,61]. Current thinking suggests that severe malaria is caused
by parasites expressing an antigenically-restricted subset of variant
surface antigens [2], probably encoded by Group A var genes
[29,30]. Such an ‘‘antigenically-restricted’’ subset of parasites
would be expected to have variant surface antigens (probably
PfEMP1) showing conserved sequence and/or conserved epitopes
that would be recognised by antibodies that show surface reactivity
with diverse parasite strains. The findings reported here, that
antibodies raised to PfEMP1 variants from IgM-positive rosetting
parasites show surface reactivity with diverse parasite strains
sharing the same virulence-associated phenotype, may represent
the first example of such an ‘‘antigenically-restricted’’ subset of
parasites. Our data are suggestive of shared PfEMP1 epitopes
amongst the IgM-positive rosetting lab strains and clinical isolates,
however, further work will be necessary to identify such epitopes
and exclude the possibility that the strain-transcending antibodies
are recognising altered host proteins or conserved parasite proteins
on the surface of IEs (although no such parasite-derived conserved
surface proteins have yet been demonstrated).
All of the parasite lines studied here consisted of heterogeneous
mixtures of different variants due to var gene switching which
occurs spontaneously in vitro. This heterogeneous mixture can lead
to some difficulties in interpretation of data. For laboratory strains
selected for rosetting, the percentage of homologous antibody
positive cells varied between 30–75% and closely matched the
rosette frequency of the culture. For the IgM-positive rosetting
laboratory strains we were able to show by dual staining that the
PfEMP1 antibodies (homologous and heterologous) were binding
to the IgM-positive IE population (Figure 3 and S3). Ideally future
work should focus on parasite strains that have been selected by
FACS-sorting and panning with specific antibodies to be
essentially mono-variant (.90% single variant) as described by
Vigan-Womas et al [12]. However, this is technically extremely
demanding, especially with parasites expressing Group A-mediat-
ed PfEMP1 phenotypes such as rosetting, which are rapidly lost
during in vitro culture due to switching away from Group A var
genes [65]. For the clinical isolates, interpretation of data from
heterogeneous mixtures of variants is also a problem, and ideally
dual staining experiment should be performed to identify
unequivocally the subpopulations recognised by homologous and
heterologous antibodies. This was not done here, and lack of
material prevented further experiments being carried out.
However, a strong positive correlation between the percentage
of IEs positive for IgM and PfEMP1 antibodies supports the
suggestion that the IgM-positive cells were being recognised by the
PfEMP1 antibodies, although further work will be needed to test
this directly. In addition, further examination of the effector
functions of the heterologous PfEMP1 antibodies on clinical
isolates would be desirable, including rosette inhibition, phagocy-
tosis and other potential immune clearance mechanisms such as
complement mediated lysis. It is not known which of these effector
functions would be required for parasite clearance in vivo, although
it seems likely that surface reactive antibody could lead to
clearance via a variety of different mechanisms.
The ability to induce strain-transcending antibodies by
immunization with a small number of PfEMP1 NTS-DBLa
recombinant proteins as shown here, raises the possibility of
developing therapeutic interventions to prevent rosetting. Roset-
ting is known to be a major P. falciparum virulence factor,
supported by disease-association studies, animal models and
human genetics (reviewed in [19]). However, the exact contribu-
tion of rosetting to severe malaria is hard to quantify, and it is
unclear how many severe malaria cases could be prevented or
treated by an effective anti-rosetting therapy. Other parasite
adhesion phenotypes such as platelet-mediated clumping [66,67]
or ICAM-1 binding [68] may contribute to the pathogenesis of
severe malaria, although this remains controversial [69–72]. A
complete understanding of the patho-physiological mechanisms
Figure 8. Polyclonal PfEMP1 antibodies do not recognise human IgM. a) ELISA for recognition of human IgM. The positive control is an anti-
human IgM antibody. The mean and SD of Optical Density (OD) values from triplicate wells are shown. b) Flow cytometry of IT/PAR+ parasites grown
with and without human IgM and stained with TM284var1 antibodies.
doi:10.1371/journal.ppat.1002665.g008
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leading to severe malaria and the role of specific adhesion
phenotypes in these pathways remains elusive, and is an important
area for further research. Currently, rosetting is the most well-
substantiated virulence factor in human malaria, and human
genetic studies showing that rosette-reducing erythrocyte poly-
morphisms reduce the odds ratio for severe malaria by up to two-
thirds [38,39], suggest that there is considerable clinical benefit to
reducing rosetting. The strain-transcending antibodies against
IgM-positive rosetting parasites reported here were generated by
immunizing rabbits with NTS-DBLa domains of PfEMP1. If
similar responses could be raised in humans, this would raise the
possibility of an anti-rosetting vaccine to prevent some cases of
severe malaria. Alternatively, if shared PfEMP1 epitopes can be
identified and mapped, it may be possible to target them with
small molecule drugs to disrupt rosettes, and so develop an
adjunctive therapy for severe malaria. It is interesting to note that
because of the effect of ABO blood group on rosetting (rosettes
form poorly in group O erythrocytes [33,73] and group O
individuals are partially protected from severe malaria [39,74]),
any anti-rosetting intervention would be predicted to have most
pronounced clinical benefit for patients with non-O blood groups.
Group O individuals can still suffer from severe malaria however,
therefore although anti-rosetting interventions clearly have
potential for prevention or adjunctive therapy of severe disease
[19], they are likely to be most useful as part of a cocktail of anti-
severe disease measures.
Further development of anti-rosetting therapies would be aided
by a more detailed understanding of the role of particular rosetting
phenotypes in the development of severe malaria. In particular,
the relative contributions of IgM-positive and IgM-negative
rosetting phenotypes to severe malaria have received little
attention to date. The only study to examine IgM-positive
rosetting in clinical isolates with specific reagents found a strong
positive correlation between IgM-binding and rosetting and severe
disease, although rosetting was the more strongly-associated
variable [41]. Other studies of rosetting and severe malaria
(reviewed in [19]) have not investigated the IgM-binding
phenotype of the parasites, therefore more research in this area
is desirable.
The biological function of the human IgM bound to the surface
of P. falciparum IEs has also received relatively little attention to
date [75]. Initial studies suggested that rosetting parasites can bind
both IgG and IgM from normal human serum and that this is
important for strengthening rosettes [40,76]. However, subsequent
studies using specific mAb reagents to detect human immuno-
globulins showed only IgM, but not IgG on the surface of rosetting
IEs [41]. Non-immune IgM (but not IgG) was also detected on the
IE surface of CSA-binding parasites implicated in placental
malaria [46], whereas parasite strains showing other common
adhesion phenotypes such as CD36-binding, ICAM-binding and
platelet-mediated clumping do not bind non-immune immuno-
globulins [41]. Further studies of rosetting and CSA-binding
parasites confirmed that non-immune IgG does not bind to IEs,
and used domain swap antibodies based on an IgG backbone to
show that the Cm4 domain of IgM is required for binding to
PfEMP1 [50]. Recent data from parasites expressing var2CSA
suggest that IgM-binding might be an immune evasion mechanism
that makes PfEMP1 less accessible to specific antibodies [44].
One unexplained feature of the current data is why antibodies
to IgM-positive rosetting PfEMP1 variants show strain-transcen-
dent activity, whereas antibodies to IgM-negative rosetting
PfEMP1 variants do not, despite apparently equivalent amino
acid diversity in the two sets of variants. We considered the
possibility that the IgM itself could be the cause of the cross-
reactivity, however we showed that the PfEMP1 antibodies did not
recognise human IgM in an ELISA, and the PfEMP1 antibodies
still recognize heterologous strains when the parasites were grown
in the absence of human IgM (Figure 8). It may be that a small
sequence motif such as one of the homology blocks described by
Rask et al [6] present only in the IgM-positive variants may explain
the cross-reactivity. Additional examples of IgM-positive rosetting
variants and detailed mapping of epitopes recognised by strain-
transcending antibodies will be needed to investigate this
possibility. Alternatively, it is possible that the binding of IgM to
PfEMP1 affects its tertiary or quaternary structure, making it more
accessible to antibodies directed against the N-terminus of the
molecule.
Another poorly understood aspect of rosetting is the precise
contribution of different parts of the PfEMP1 molecule to rosette
formation, and the relationship between the IgM-binding and
erythrocyte-binding regions of PfEMP1. Previous data show that
the primary receptor-ligand interaction in rosetting occurs
between NTS-DBLa of specific PfEMP1 variants and receptors
on uninfected Es [12,22,23]. However, the IgM-binding region of
PfEMP1 maps to a different part of the molecule (the final or
penultimate DBLe or DBLf domain before the transmembrane
region [49,50] and AG and JAR, unpublished data). IgM is
thought to enhance rosetting by strengthening the adhesive
interactions between infected and uninfected Es [40,42,43].
Whether it does this by ‘‘bridging’’ between the IE and receptors
on uninfected Es [43], or by altering the conformation of PfEMP1
to enhance its affinity for erythrocyte receptors is unclear.
However, IgM on its own is not sufficient to cause rosetting; for
example, CSA-binding parasites bind IgM but do not rosette [46].
Based on our current data, we suggest that antibodies to NTS-
DBLa block rosetting by directly interfering with the receptor-
ligand interaction between PfEMP1 and erythrocyte receptors.
The NTS-DBLa antibodies do not affect IgM binding, because
dual-staining experiments showed that human IgM is detected on
the surface of rosetting IEs even in the presence of PfEMP1
antibodies (Figure 3 and S3). Exactly how IgM-binding influences
PfEMP1 function and contributes to rosette formation is not clear
and will require further work.
One of the main findings from this study is the identification of a
clear subset of Group A PfEMP1 variants expressed by IgM-
positive rosetting parasites, exemplified by variant HB3var6 from
strain HB3R+, variant TM284var1 from strain TM284R+ and
variant ITvar60 from strain IT/PAR+. ITvar60 has previously
been linked to rosetting in two other IT/FCR3-derived parasite
lines [77,78], and is confirmed here as an IgM-positive rosetting
variant. This subset of Group A PfEMP1 variants from IgM-
positive rosetting parasites show two out of eight possible
subclasses of DBLa1 domain (DBLa1.5 or DBLa1.8) [6] and a
set of three DBLe/DBLf domains adjacent to the transmembrane
region (Figure 1). Rask et al [6] recently presented an alternative
way of assessing PfEMP1 types by looking at ‘‘domain cassettes’’
(sets of PfEMP1 domains that usually occur together). They
identified seven domain cassettes commonly found in Group A var
genes [6]. Our data suggest that two of these domain cassettes are
linked to the IgM-positive rosetting phenotype: domain cassette
16, characterised by DBLa1.5 linked to CIDRd delta as seen in
HB3var6, and domain cassette 11 characterised by DBLa1.8
linked to CIDRb2 and DBLc7 as seen in ITvar60 and
TM284var1. The clinical isolates we studied showed surface
reactivity with either HB3var6 antibodies (DBLa1.5/domain
cassette 16) or TM284var1 antibodies (DBLa1.8/domain cassette
11), but rarely with both (Figure 6). These data are suggestive that
these two main DBLa1 types may underlie the IgM-positive
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rosetting phenotype in diverse field isolates, although further
sequence information is needed to substantiate this idea.
Other variants with similar PfEMP1 architecture to the IgM-
positive rosetting variants described here can be seen in the
genome of a recently sequenced P. falciparum strain IGH
(IGHvar12, IGHvar 22 and IGHvar 24 [6]). Furthermore, an
ITvar60-like variant occurs in the sequenced P. falciparum strain
D10 from Papua New Guinea (http://www.broadinstitute.org).
Taken together, these data suggest that variants with the IgM-
positive rosetting type of PfEMP1 architecture occur commonly in
geographically diverse P. falciparum isolates. One limitation of the
current study was that there was insufficient material from the
clinical isolates to allow us to identify and sequence their expressed
var genes. The selection of IgM-positive rosetting parasites from
culture-adapted clinical isolates (Figure 7) will allow us to examine
their var genes in further detail. The correct identification of
rosette-specific variants (Table S1) and sequencing of full-length
var genes remains a laborious and time-consuming process for
isolates that do not have a full genome sequence available.
However, wider studies of PfEMP1 architecture and sequence
from rosetting clinical isolates will be essential for a full
understanding of how the antibody cross-reactivity documented
here relates to sequence diversity and PfEMP1 type.
In summary, these data show that antibodies raised against a
subset of Group A PfEMP1 variants from IgM-positive rosetting
laboratory strains show surface reactivity and rosette inhibition
against heterologous parasites sharing the same adhesion pheno-
type. These data suggest shared surface epitopes amongst P.
falciparum isolates with a shared virulence-associated phenotype; a
phenomenon that may underlie the epidemiological observations
that children acquire immunity to life-threatening malaria after a
small number of infections [14,64]. Most importantly, the ability
to elicit strain-transcendent antibodies by immunizing with key
PfEMP1 variants underlying a virulence phenotype, suggests that
designing interventions to prevent severe malaria is a realistic goal.
Materials and Methods
Ethics statement
Collection of clinical isolates (blood samples) from malaria
patients was carried out in accordance with the Declaration of
Helsinki. Written informed consent was obtained from the
patients’ parents or guardians and was approved by the Lothian
Regional Ethical Review Committee (LREC//2002/4/34), the
KEMRI Ethical Review Committee, the Gambia Government/
MRC Laboratories Joint Ethics Committee, the Cameroon
Ministry of Public Health Regional Ethics committee and the
University of Bamako Institutional Review Board. Animal
immunisations were carried out commercially by BioGenes
GmbH (Berlin, Germany) according to European Union guide-
lines 86/609/EWG of 24.11.1986 and the European Agreement
of 18.3.1996 for protection of animals used for scientific purposes.
Parasites and parasite culture
The P. falciparum laboratory strains (HB3, TM284, IT/PAR+,
Muz12, IT/R29 and TM180) were cultured in supplemented
RPMI with 10% pooled normal human serum as described [79].
Each strain was separated into isogenic rosetting (R+) and non-
rosetting (R2) sub-populations by gelatin flotation or centrifuga-
tion though 60% Percoll [48]. For consistency, the rosette-selected
strains are here designated ‘‘strain name R+’’ throughout (eg.
HB3R+) except for IT/R29 (where the ‘‘R’’ indicates rosetting).
Repeated rosette selection [48] of the R+ strains (2–3x per week)
was required to maintain the rosetting phenotype, which is
otherwise rapidly lost in vitro. The rosette frequency is the
percentage of IEs in rosettes out of 200 IEs assessed by microscopy
of an ethidium-bromide-stained wet preparation as described [80].
The rosette frequency of selected parasites varied between 30–
75% depending on the frequency of rosette selection and var gene
switching (which occurs spontaneously in vitro). The IgM-binding
phenotype of the rosetting strains was determined by immunoflu-
orescence assay (IFA) with an anti-human IgM mAb (Serotec
MCA1662 1/500 dilution) as described [41]. The IgM phenotype
of TM284R+ and IT/PAR+ (IgM-positive rosetting) and IT/R29
and TM180R+ (IgM-negative rosetting) has been reported
previously [41]. HB3R+ shows IgM-positive rosetting (Figure 3
and Table S9) whereas Muz12R+ shows predominantly IgM-
negative rosetting (Table S9). With some strains (eg. TM284R+
and HB3R+) the IgM-positive IEs can be seen to be in rosettes
after the IFA. However, in others (eg. IT/PAR+) the rosettes are
disrupted by repeated washing during the IFA, and in these cases
the designation of IgM-positive rosetting relies upon consistent
strong positive correlation between the percentage of rosette-
forming and IgM-positive IEs in repeated experiments. All
cultures were checked regularly to exclude mycoplasma contam-
ination [81]. The parasites were genotyped with primers to MSP1,
MSP-2 and GLURP [82] and were genetically distinct apart from
IT/PAR+ and IT/R29 which share the same genotype but
transcribe different predominant PfEMP1 variants.
Other parasite strains used were unselected HB3 and 3D7
(CD36-binding), IT/A4 (CD36 and ICAM-1 binding) and three
strains selected for binding to human brain endothelial cells (HB3-
HBEC, 3D7-HBEC and IT-HBEC [83]). These strains all have
,5% IgM-positive IEs by IFA.
Clinical isolates were from Cameroon (CAM1), Kenya (KEN7,
KEN14, KEN17, 9197, SA075), Mali (MAL27, MAL34, MAL43,
MAL81,MAL103) and The Gambia (GAM627). All clinical isolates
were cryopreserved from previous studies and were selected because
records showed they had a rosette frequency of 20% or higher in the
first asexual cycle in vitro when fresh. The Malian isolates were
collected in Bamako in 1996 as part of a pilot study on rosetting and
malaria severity in Mali. Kenyan isolates KEN7, KEN14 and
KEN17 were collected as part of a case-control study on severe
malaria [84], while 9197 and SA075 were from studies on var gene
diversity in Kenya [85]. The Gambian isolate GAM627 was
collected in 2009–2010 as part of a study on rosette-inhibiting drugs
(Rowe et al, unpublished data). During the Gambian study, 23
isolates from severe malaria patients were collected of which seven
had .20% rosette frequency and .1% parasitaemia, but only one
of these was cryopreserved (GAM627) and therefore suitable for use
in this study. The Cameroonian isolate CAM1 was collected in
2009–10 as part of a study on var gene transcriptional profiling and
clinical malaria severity (Rowe et al, unpublished data). Of 38
isolates collected from severe and uncomplicated malaria patients,
only three showed.20% rosette frequency.1% parasitaemia and
only one of these (CAM1) grew after thawing.
For all clinical isolates, an aliquot was put into culture at the time
of original collection and its rosette frequency determined as
described [33]. The remainder of the sample was cryopreserved
within 12 hours of the blood sample being drawn and was not
cultured prior to freezing. These cryopreserved samples were used
for this study. The isolates were thawed as described [80] and were
tested for surface reactivity and rosette inhibition with PfEMP1
antibodies and controls as described for laboratory strains.
Experiments were carried out in the first cycle after thawing,
except for 9197 and SA075 which had been adapted to culture,
cloned and selected for rosetting over 3–4 months of in vitro growth.
The IgM-binding phenotype of the rosetting clinical isolates was not
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determined during their initial collection in the studies outlined
above, but was determined after thawing by IFA with an anti-
human IgM mAb as described above for the laboratory strains.
Var gene expression profiling and var gene sequencing
RNA extraction and var gene expression profiling were carried
out as described previously [27] and in Table S1. The full-length
sequence of each predominant rosette-specific var gene was derived
from the sequence tag by: a) extraction from parasite genome
databases (HB3 at http://www.broadinstitute.org and IT at www.
sanger.ac.uk) b) PCR-walking, cloning and sequencing using
degenerate primers to upstream and downstream PfEMP1 regions
[86] forMuz12var1. c) PCR-walking, cloning and sequencing using
vectorette libraries [22] for TM284var1 and TM180var1. The
GenBank Accession numbers for the sequences studied here are
Y13402 (ITvar9/R29var1), EF158099 (ITvar60), JQ684046
(TM284var1), JQ684047 (TM180var1) and JQ684048 (Muz12var1).
The HB3var6 sequence can be obtained from http://www.
broadinstitute.org/annotation/genome/plasmodium_falciparum_
spp/MultiHome.html gene reference PFHG_02274.1. DNA se-
quence analysis was done using DNAstar Lasergene (DNAstar Inc.)
Northern blotting
RNA extraction and Northern blotting of isogenic rosetting and
non-rosetting pairs of parasites was carried out with Digoxigenin-
labelled RNA probes as described [50]. RNA (1.5 mg per lane) was
electrophoresed on a 1.2% agarose/1.1% formaldehyde gel and
transferred onto a nitrocellulose membrane. For each parasite strain,
the blot was hybridised with a specific RNA probe representing one
DBL domain from the homologous rosette-specific var gene, as well as
an exon II probe to detect all var genes. Probes were generated with
the following primers: HB3var6, CIDRd, forward 59-tctcgtcagctggat-
gaaagtaattctcatag-39 (the italicized region indicates a restriction site
added to the primers for other experiments; the gene specific
sequence is in regular font), reverse 59-acgagtgggccctccaataagtttcttcac-
cat-39; ITvar60, 5th DBL domain, forward 59-tctcgtcagctggaggaatatcct-
gaagaatac-39, reverse 59-acgagtgggccccaaattacattcaccttc-39; Muz12var1,
DBLc, forward 59-gtagcagaagatggtgcttg-39, reverse 59-ctttccacttta-
taagcc-39; TM180var1, DBLb, forward 59-gaacagggtgaaaacacta-39,
reverse, 59-caagcttgtgtgcacctctg-39; Exon II, forward 59- aaaaaac-
caaagcatctgttggaaatttat-39, reverse 59-gtgttgtttcgactaggtagtaccac-39.
High stringency conditions (specific var gene probes) were hybridisa-
tion at 58uC overnight, followed by washing at 62uCwith 0.56SSC/
0.1%SDS for 45 mins followed by 0.256 SSC/0.1%SDS for
45 mins. Moderate stringency conditions (Exon II probe) were
hybridisation at 52uC overnight, followed by washing at 55uC with
0.56SSC/0.1%SDS for 45 mins followed by 0.256SSC/0.1%SDS
for 45 mins.
Recombinant proteins and polylconal antibodies
Recombinant proteins were produced as described previously
[13]. The domain boundaries for the NTS-DBLa recombinant
proteins for each rosette-specific variant were as follows: HB3var6
Met1-Pro473; TM284var1 Met1-Pro457; ITvar60 Met1-Pro464;
Muz12var1 Met1-Pro458; TM180var1 Met1-Pro485. The non-
rosetting Group A PfEMP1 variant HB3var3 (Met1-Pro468) was
used as a control (Claessens and Rowe et al, submitted). The His-tags
used for protein purification were cleaved by TEV protease before
immunization as described [13]. Each protein was used to
immunize two rabbits which had been pre-screened as described
[13] to avoid animals with pre-existing natural antibodies to human
erythrocytes or malaria parasites. Immunization and serum
collection were carried out by BioGenes GmBH (Berlin, Germany).
Rabbits were immunized with 250 mg of protein on day 0 and with
100 mg on day 7, 14 and 28 and 49. Immunizations were carried out
using an adjuvant developed by Biogenes GmbH that contained
0.23% of lipopolysaccharides of the blue-green algae Phormidium
spp, 92.8% mineral oil, 3.48% Tween-20, 3.48% Span-80. Final
bleed antisera were collected on day 56. Total IgG purification was
carried out by Biogenes, and all antibody concentrations given in
mg/ml throughout this manuscript are concentrations of total IgG.
Immunofluorescence assays (IFA)
Immune and pre-immune sera were tested in IFA with live IEs
as described [13,50]. Out of each pair of immunized rabbits, the
serum giving the brightest fluorescent signal with the lowest
background was chosen for purification of total IgG. In all cases,
both rabbit sera gave positive PfEMP1-staining, with only minor
differences in intensity of staining. The percentage of IEs staining
with the PfEMP1 antibodies and the anti-human IgM mAb was
assessed by counting 100 DAPI-stained IEs per slide. IFA slides
were viewed using a Leica DM LB2 fluorescence microscope and
images taken with a Leica DFC300FX digital camera. Images
were handled using Adobe Photoshop and underwent cropping
and minor adjustments to brightness and contrast. All adjustments
were applied equally to PfEMP1 antibody and control images.
Flow cytometry
Staining for flow cytometry was carried out as for IFA [13,50],
except that 1.25 mg/ml Hoechst 33342 stain (Sigma) was used
instead of DAPI to stain IEs and 50 mg/ml fucoidan was added
after the secondary incubation washes to disrupt rosettes. Staining
and washes were carried out on live (unfixed) cells, but before
FACS analysis, cells were fixed with 0.5% paraformaldehyde, with
50 mg/ml fucoidan added to prevent rosettes from re-forming.
500,000 events per sample were analyzed on a Becton-Dickinson
LSRII flow cytometer. Flow cytometry data were analyzed using
FlowJo software (Tree Star Inc.).
Flow cytometry of trypsinised parasite cultures
Parasite cultures of mature pigmented trophozoites with a
rosette frequency of at least 30% were used for trypsinisation
experiments. 20 ml of packed cells from a parasite culture were
centrifuged and washed twice in incomplete RPMI. The cells were
resuspended in 500 ml of 10 mg/ml of TPCK-trypsin (Sigma) or
incomplete RPMI (called ‘‘mock trypsin’’), mixed and incubated at
room temperature for 5 mins. The reaction was stopped by adding
500 ml of 1 mg/ml of Soybean trypsin inhibitor (Sigma) to the
trypsin-treated and mock trypsin samples, which were mixed and
incubated at room temperature for 5 mins. The samples were
centrifuged at 4000 rpm for 2 mins and washed twice in
incomplete RPMI and once in PBS. The cells were resuspended
in PBS containing 1% BSA and 1.25 mg/ml of Hoechst, and
staining was carried out as described for IFA and flow cytometry
above. All antibodies were used at a final concentration of 100 mg/
ml except for anti-NTS-DBLa (HB3var6), which was used at
400 mg/ml when tested against the parasite strain 9197.
Dual colour IFA
Dual colour IFA were carried out to test whether the
homologous and heterologous (cross-reactive) antibodies bind to
the IgM-positive rosetting IE population. Staining was carried out
as above with the primary incubation containing both 1/500 of
mouse monoclonal anti-human IgM (Serotec MCA 1662) and
20 mg/ml of rabbit polyclonal NTS-DBLa antibodies. Secondary
incubations were carried out with a mixture of 1/1000 dilution of
highly cross-absorbed Alexa Fluor 488 goat-anti rabbit IgG
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(Invitrogen) and 1/1000 dilution of highly cross-absorbed Alexa
Fluor 594 goat anti-mouse IgG (Invitrogen). In addition to a
secondary only control, and a mouse isotype control plus rabbit IgG
control, combinations of single stains were used to rule out any non-
specific binding of Alexa Fluor 488 anti-rabbit to mouse anti-human
IgM and of Alexa Fluor 594 anti-mouse to rabbit IgG. The
percentage of PfEMP1-positive cells that were positive for IgM and
vice versa were determined by counting 100 positive IEs per slide.
Rosette inhibition experiments
P. falciparum cultures at ring stage were incubated overnight with
antibodies and controls at various dilutions, and rosetting assessed
the next day by microscopy as described [13]. Antibodies at the
highest concentration (1 mg/ml) were dialysed before use to remove
non-specific growth-inhibitory factors. Approximately 200 ml of
total IgG was added to a dialysis cassette (Pierce) and dialysis was
carried out against 500 ml of PBS overnight at 4uC. The rosette
frequency (RF) is the percentage of mature (pigmented trophozoite)-
IEs binding two or more uninfected Es from 200 IEs counted.
Phagocytosis assays
Phagocytosis experiments with Thp-1 cells were as described
previously [13] except that fucoidan (200 mg/ml) was used for
parasite purification and rosette disruption. The positive control
was parasite culture opsonized with 90 mg/ml of a rabbit anti-
human erythrocyte antibody (ABCAM ab34858). Muz12var1
antibodies were not included in the phagocytosis assays because
they show some background binding to uninfected Es.
Selection for IgM-positive IEs
Parasites were selected for IgM-positive IEs using M-450 Epoxy
Dynabeads (Dynal) coated with a mouse anti-human IgM mAb
(Serotec MCA1662) as described [87].
ELISA
The ability of PfEMP1 antibodies to cross react with human IgM
was tested using purified human IgM (5 mg/ml, Rockland) coated
onto an ELISA plate at 4uC overnight. After blocking for 1 hour in
PBS containing 0.05% Tween 20 (PBST) and 5% milk, wells were
incubated with 10, 1 and 0.1 mg/ml of rabbit polyclonal NTS-DBLa
antibodies in PBST containing 1% milk (PBSTM). After 1 hour
incubation at room temperature, wells were washed with PBST and
incubated with 1:10,000 anti-rabbit IgG-HRP (Sigma) in PBSTM for
a further hour. After washing as above, reactions were developed by
incubating the wells with substrate 3,39,5,59-tetramethylbenzidinedi-
hydrochloride (Sigma) according to the manufacturer’s instructions
and absorbance was measured at a wavelength of 450 nm. As a
positive control, a rabbit anti-human IgM F(ab’)2-HRP (DAKO) was
used at 1:100 (10 ag/ml), 1:1000 (1 mg/ml) and 1:10000 (0.1 mg/ml).
A set of ELISA experiments were carried out to test the ability of
rabbit polyclonal NTS-DBLa antibodies to recognise homologous
and heterologous recombinant NTS-DBLaproteins. The method was
as described for the IgM ELISA except that wells were coated with
2 mg/ml recombinant NTS-DBLaprotein and antibodies were used
at a range of concentrations from 0–10 mg/ml. Blocking, washing,
incubation and detection was carried as described for the IgM ELISA.
Heterologous surface reactivity of PfEMP1 antibodies in
the absence of IgM
Pooled human serum was depleted of IgM by three successive
rounds of incubation for 45 mins at room temperature on a rotating
wheel (15 rpm) with an equal volume of anti-human IgM (m-chain
specific)-agarose (Sigma A9935). The absence of IgM in the absorbed
serum was confirmed by western blotting with an anti-human IgM
monoclonal antibody. IT/PAR+ parasites were grown from ring
stage overnight in supplemented RPMI with 10% IgM-depleted
serum, and an aliquot (positive control culture) was incubated with
1 mg/ml of human IgM (Calbiochem) for 1 hour at 37uC. The IgM-
negative and IgM-positive cultures were then washed and testing for
surface reactivity with heterologous PfEMP1 antibodies to
TM284var1 NTS-DBLa by flow cytometry as described above.
Software
Graphing and statistical analysis were done using Prism
(GraphPad Software).
Supporting Information
Figure S1 Alignment of NTS-DBLa domains from
rosetting PfEMP1 variants. Sequences were aligned by Clustal
W. Amino acid residues that match the consensus sequence are
shaded black. The rosetting variants are as described in this work
plus ITvar9 [22], Palo Alto Var O [23] and PF13_0003 [12].
(TIF)
Figure S2 Western blotting with polyclonal antibodies
to PfEMP1. Triton-X-100 souluble (Tx) and Triton-X-100
insoluble/SDS soluble (SDS) extracts of parasite cultures and
uninfected Es (RBC) were electrophoresed on 3–8% Tris-acetate
gels, transferred to PVDF membrane and probed with antibodies
to PfEMP1. a) 6H1 PfEMP1 mAb (1/1000) tested on IT/PAR+
parasites. b) 6H1 PfEMP1 mAb (1/1000) tested on IT/R29
parasites. c) 6H1 PfEMP1 mAb (1/1000) tested on IT/PAR+
parasites. d) ITvar60 NTS-DBLa rabbit polylconal antibodies (1/
15,000) tested on IT/PAR+ parasites. Parasite-specific high
molecular weight bands consistent with PfEMP1 are arrowed.
See Text S1 for further details and methods.
(TIF)
Figure S3 Homologous and heterologous polyclonal
antibodies to PfEMP1 recognize IgM-positive IEs. a)
Parasite strain TM284R+ was stained in a live cell IFA with a
mixture of rabbit polylconal antibodies to PfEMP1 (homologous or
heterologous) at 20 mg/ml and mouse anti-human IgM mAb
(Serotec MCA1662 1/500 dilution). Secondary incubation was with
a mixture of Alexa Fluor 488 conjugated anti-rabbit IgG (1/1000)
and Alexa Fluor 594-conjugated anti-mouse IgG (1/1000). IEs were
stained with DAPI (1 mg/ml; scale bar 10 mm). IgM-positive IEs
(right column) show punctate/rim surface fluorescence with both
homologous antibodies (anti-TM284var1, 2nd row, middle column)
and heterologous antibodies (anti-ITvar60, 3rd row, middle
column). 94–100% of the PfEMP1 antibody-positive cells were
IgM-positive, and 100% of the IgM-positive cells were PfEMP1-
antibody positive. At this concentration TM180var1 antibodies give
very faint punctate fluorescence on IgM-positive IEs (5th row,
middle column) whereas HB3var6 antibodies are negative (4th row,
middle column). At higher concentrations (100–400 mg/ml) both
TM180var1 and HB3var6 antibodies stain IgM-positive IEs. b)
Specificity controls (with parasite strain TM284R+ as above) show
that the Alexa 488 conjugated anti-rabbit IgG secondary does not
recognise the mouse anti-human IgM mAb (top row) and that the
Alexa 594-conjugated anti-mouse IgG does not recognise the rabbit
polyclonal antibodies (bottom row). Camera exposure settings and
image handling were identical for PfEMP1 antibodies and controls.
(PDF)
Figure S4 Trypsin-sensitivity of IE surface molecules
recognized by heterologous polyclonal PfEMP1 antibod-
ies. a) Flow cytometry of live IEs of P. falciparum strain TM284R+
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stained with homologous (anti-TM284var1) and heterologous (anti-
ITvar60 and anti-TM180var1) PfEMP1 antibodies (100 mg/ml of
total IgG). The negative control was IgG from a non-immunized
rabbit (rabbit IgG). IEs were stained with Hoechst and rabbit IgG
bound to the surface of IEs was detected with highly cross-absorbed
Alex Fluor 488-conjugated anti-rabbit IgG at 1/500 dilution. The IE
molecules recognised by PfEMP1 antibodies were sensitive to trypsin
(right column) (10 mg/ml trypsin for 5 mins at room temperature
(RT), followed by 1 mg/ml of trypsin inhibitor for 5 mins at RT). b)
Flow cytometry of live IEs of P. falciparum strain IT/PAR+ stained
with homologous (anti-ITvar60) and heterologous (anti-TM284var1
and anti-HB3var6) PfEMP1 antibodies (100 mg/ml of total IgG).
Rabbit IgG control and dilutions as above. Trypsin treatment was as
above except using 1 mg/ml trypsin. For IT/PAR+ the IE
molecules recognised by both homologous and heterologous
PfEMP1 antibodies are trypsin-resistant.
(PDF)
Figure S5 Recognition of recombinant NTS-DBLa do-
mains by homologous and heterologous antibodies by
ELISA. Recombinant NTS-DBLa domains of the PfEMP1
variants encoded by HB3var6, TM284var1, ITvar60, Muz12var1,
TM180var1 and ITvar9 were coated at 2 mg/ml and incubated with
NTS-DBLa antibodies over a range of concentrations from 0–
10 mg/ml. Binding was detected using 1:10,000 dilution of anti-
rabbit IgG-HRP (Sigma). The mean and SD of Optical Density
(OD) values from triplicate wells are shown. a) rabbit IgG control, b)
anti-HB3var3, c) anti-ITvar9, d) anti-TM180var1, e) anti-Muz12-
var1, f) anti-TM284var1, g) anti-HB3var6 and h) anti-ITvar60.
(PDF)
Figure S6 Opsonisation and induction of phagocytosis
by polyclonal PfEMP1 antibodies. IEs were stained with
ethidium bromide and opsonised with PfEMP1 antibodies over a
range of concentrations (1.56–400 mg/ml) before incubation with
the monocytic cell line Thp-1. Thp-1 cells that phagocytosed IEs
were detected by flow cytometry. a) parasite strain TM284R+, b)
parasite strain HB3R+, c) parasite strain IT/R29, d) parasite strain
TM180R+. Data are shown as percentage of the positive control
opsonised with a rabbit anti-human erythrocyte antibody
(ABCAM ab34858 at 90 mg/ml). The ‘‘Non Ros Group A’’
negative control consists of antibodies to HB3var3, a PfEMP1
variant that is not involved in rosetting. HB3R+ parasite culture
contains a subpopulation of non-rosetting IEs expressing HB3var3
(see Table S1) which explains why phagocytosis was induced in
this case. The ‘‘Control Rabbit IgG’’ is a negative control
consisting of IgG from a non-immunized rabbit.
(PDF)
Table S1 Identification of a predominant rosette-spe-
cific var gene by transcriptional profiling of isogenic
rosetting (R+) and non-rosetting (R2) HB3 parasites.
(DOC)
Table S2 Pair-wise amino acid identities for NTS-
DBLa, CIDR1 and DBLc from rosetting PfEMP1 vari-
ants.
(DOC)
Table S3 Pair-wise amino acid identities for DBLe from
rosetting PfEMP1 variants.
(DOC)
Table S4 Pair-wise amino acid identities for DBLf from
rosetting PfEMP1 variants.
(DOC)
Table S5 Pair-wise amino acid identities for DBLb from
rosetting PfEMP1 variants.
(DOC)
Table S6 Pair-wise amino acid identities for DBLd from
rosetting PfEMP1 variants.
(DOC)
Table S7 Pair-wise amino acid identities for CIDR2
from rosetting PfEMP1 variants.
(DOC)
Table S8 Summary of PfEMP1 antibody activity against
homologous parasite strains.
(DOC)
Table S9 IgM phenotype of HB3R+ and Muz12R+
parasites.
(DOC)
Text S1 Western blots to detect ITvar60 PfEMP1.
(DOC)
Text S2 Reactivity of PfEMP1 antibodies with recom-
binant NTS-DBLa recombinant proteins by ELISA.
(DOC)
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